2-Peptide Stack (CJC + one additional peptide): $795 per cycle
No therapeutic, prophylactic, or diagnostic application is claimed or implied, and the peptide is not approved for human or veterinary use in Australia
it has expanded to include dietary choices, exercise protocols, and nutritional supplements positioned within the same thematic space
Conclusions GLP-1RA medications have progressed beyond another tool for clinicians to manage type 2 diabetes, overweight, and obesity to therapies with robust cardiovascular outcomes
A blanket statement that Medicare never covers weight-loss GLP-1 medicines is no longer accurate in August 2026
Sahni will develop a customized treatment plan that incorporates tirzepatide alongside lifestyle modifications such as healthy eating and increased physical activity